Print
17 April 2014
Marchmont Innovation News
The partners in the large Nuclear Medicine Center project in Vladivostok in Russia’s Far East have agreed that the future facility will use Russian equipment, the official website of the Primorsky regional administration announced earlier this week.
According to the message, at the most recent meeting Governor Vladimir Miklushevsky of Primorsky, Anatoly Chubais, the president of Rusnano, Russia’s nanotech giant, and Sergei Kirienko, the CEO of Rosatom, the national umbrella for nuclear energy assets, worked out the fundamental principles of pushing the project as a private-public partnership. The future Nuclear Medicine Center is expected to enable a mutually beneficial combination of the treatment of patients and medical R&D.
According to Rosatom’s Kirienko, research that’s being conducted on the campus of Far East Federal University, the largest such institution in Vladivostok and the entire region, will help attract international specialists in the nuclear field.
“We talk about on-the-job retraining for physicians and the training of new doctors. It’s important that the Center use Russian-made equipment for specialists to tap when studying here,” Mr. Kirienko said.
According to the governor, the region will raise enough private sector investment to build a cyclotron and PET scanners at the future Center.
“This will make it possible to not only diagnose cancers at early stages but also treat the diseases rapidly and efficiently,” Mr. Miklushevsky said.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.